Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly

Biologicals

Volumn 25, Issue 2, 1997, Pages 209-213

  Martin, J Tyler ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; INFLUENZA VACCINE; WATER OIL CREAM;

AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CHIRON;

EID: 0031171265     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1997.0086     Document Type: Conference Paper

References (12)

1. 1. Ott G, Barchfeld GL, Chernoff D et al. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ, eds, Vaccine Design: The Subunit and Adjuvant Approach. New York, NY: Plenum Press, 1995: chap 10.
2. 2. Beyer WEP, Palache AM, Baljet M et al. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989; 7: 385-394.
3. 3. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, eds, Options for the Control of Influenza. New York, NY: Alan R. Liss, Inc, 1986: 155-168.
4. 4. Barker WH, Mullooly JP. Effectiveness of inactivated influenza vaccine among non-institutionalized elderly persons. In: Kendal AP, Patriarca PA, eds, Options for the Control of Influenza. New York, NY: Alan R. Liss, Inc, 1986: 169-182.
5. 5. Govaert TM, Thijs CT, Masurel N et al. The efficacy of influenza vaccination in elderly individuals. JAMA 1994; 272: 1661-1665.
6. 6. Gross PA, Hermogenes AW, Sacks HS et al. The efficacy of influenza vaccine in elderly person. A meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518-527.
7. 7. Mullooly JP, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947-952.
8. 8. Nichol KL, Margolis KL, Wuorenma J et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-784.
9. 9. Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987; 77: 712-716.
10. 10. Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996; 14: 478-484.
11. 11. Martin JT. Enhanced immunogenicity of Chiron Biocine adjuvanted influenza vaccine in the elderly. In: Brown LE, Hampson AW, Webster RG, eds, Options for the Control of Influenza III. Amsterdam, Netherlands: Elsevier Science BV, 1996: 647-652.
12. 12. Dowdle WN, Kendal AP, Noble GR. Influenza viruses. In: Lenette EH, Schmidt NJ, eds. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. 5th Edn. Washington, DC: American Public Health Association; 1979: 603-605.